- Credit Type: CME
- Credit Amount: 1.75
- Cost: Free
- Release: Apr 17, 2015
- Expires: Sep 12, 2017
- Estimated Time to Complete:
1 Hour(s) , 45 Minutes
- System Requirements:
Average User Rating:
University of Alabama Birmingham
Department of Ophthalmology
Vitreous-Retina-Macula Consultants of New York
New York, NY
Needs StatementAge-related macular degeneration (ARMD) is complex disease that is one of the leading causes of vision loss worldwide. In recent years, there have been significant advances in retinal imaging technologies that have allowed clinicians and scientists to further examine diseases such as ARMD. In these combined lectures, newer imaging technologies are investigated to better understand the pathogenesis of ARMD, with an emphasis on RPE cell death.
Target AudiencePhysicians, clinical researchers, optometry students, residents, fellows and any healthcare professional interested in ophthamology
ObjectivesUpon completion of this activity particpants will be able to:
1. Discuss pathogenesis of age-related macular degeneration
2. Discuss mechanisms of RPE cell death in age-related macular degeneration
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Kentucky College of Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.
- Patient care
- Medical knowledge
Faculty DisclosureRichard F. Spaide, MD (Speaker) has relevant financial relationships with commercial interests as follows:
Topcon & Genentech - Consultant - Consultation Fee; Topcon - Royalty - Royalty Fee
No Other speakers, planners or content reviewers have any relevant financial relationships to disclose.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.
Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.